# OnCo record irae-rechallenge (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-rechallenge/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-rechallenge" ;
  schema:name "Restarting a checkpoint inhibitor after an immune-related side effect"@en ;
  schema:alternateName "immunotherapy rechallenge"@en, "ICI rechallenge"@en, "checkpoint inhibitor retreatment after irAE"@en, "resuming immunotherapy after toxicity"@en, "re-challenge after immune-related adverse event"@en ;
  schema:description "After an immunotherapy side effect has settled, your team may offer to restart the same treatment. About 3 in 10 people who restart have the same side effect again, and some side effects (such as heart or nerve inflammation, or very severe reactions) usually mean stopping for good. It is a shared decision that weighs the cancer benefit against the risk."@en ;
  schema:url <https://onco.cc/protocols/irae-rechallenge/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae" ;
  onco:related <https://onco.cc/protocols/irae-colitis/>, <https://onco.cc/protocols/irae-pneumonitis/>, <https://onco.cc/protocols/irae-hepatitis/>, <https://onco.cc/protocols/irae-myocarditis/>, <https://onco.cc/protocols/irae-neurological/>, <https://onco.cc/protocols/irae-nephritis/>, <https://onco.cc/pairings/io-rechallenge-caution-rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/rechallenge/>, <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .